Cellular Activation Therapy (CAT) | Bionica Insulin Pump

What Is Cellular Activation Therapy (CAT)?

Download our presentation on Cellular Activation Therapy here.
You'll need Adobe Reader. If you don't have it, click the logo (opens a new window)

Diabetes is a disease of improper metabolism. It is not a disease of improper blood sugars. Blood sugar excursions are just one of the symptoms of improper metabolism.

By addressing the core problem of diabetes for both Type 1 and Type 2 diabetes, the inability to metabolize carbohydrates, and the corresponding elevated lipid metabolism, this treatment slows, stops and in most cases reverses the secondary complications of diabetes. Cellular Activation Therapy using a sophisticated FDA approved pump (Bionica Microdose) and standard metabolic measurement equipment, has quietly become accepted by Endocrinologists and Diabetetologists in mainstream medicine as more and more patients are treated.

CAT works in over 90% of the patients, as it mimics the natural stimulation of the liver to produce the enzymes necessary for proper resting metabolism.

Summary
Diabetes is a disease of improper metabolism. It is not a disease of improper blood sugars. Blood sugar excursions are just one of the symptoms of improper metabolism Cellular Activation Therapy (CAT) directly corrects the core problem of diabetes, which is improper carbohydrate and lipid metabolism. This lack of proper metabolism is the direct cause of the many complications of diabetes; kidney failure, blindness, amputations, heart disease, stroke, neuropathy, progressing wounds, fatigue, sexual dysfunction, diabetic related dementia, and depression.

CAT has been known by a number of names during its clinical trials and early development, such as PIVIT, Metabolic Treatment, and Hepatic Treatment etc. They are all the same treatment, developed and owned by CATC and Bionica Inc. CAT achieves better metabolism by stimulating the liver to naturally produce the enzymes needed for proper carbohydrate and lipid metabolism.

The primary goal of the insulin pulses and the glucose meals is to provide a bimolecular (insulin and glucose) signal to the liver and other tissues to synthesize enzymes needed to catalyze a number of biochemical reactions in the liver and other tissues. The CAT therapy mimics in part the normal physiology and biochemistry of a person who does not have diabetes. With these enzymes and their related biochemical reactions in place, the liver can auto-regulate the circulating glucose levels. Without these enzymes, the liver can only overproduce glucose, leading to high glucose levels in diabetic patients, especially after meals. Insulin is delivered by the Bionica Insulin pump, an FDA, and CE approved pump. CAT using pulses of insulin and oral glycemic stimulation, provides the two (2) signals needed for the liver to perform its job of producing the enzymes that are deficient in diabetic people.

The improvement in body-wide resting metabolism is documented by standard metabolism measurement (sports) equipment. In fact, every cell uses insulin, and CAT activates proper functioning at the cellular level, hence the name Cellular Activation Therapy.

Since CAT addresses the core problem of diabetes, it is effective for both Type 1 and Type 2 diabetes. It was first used in 1984 with Type 1 patients, where the progression of the disease was slowed and in some ways stopped in the most severely ill. In 1992 studies of Type 2 patients began, and the same effectiveness has been proven for Type 2 diabetes. After 100,000 treatments, there is no doubt that the therapy works on both Type 1 and Type 2 patients.

The effects of the treatment are cumulative over weeks, months and years, at first gradually normalizing the metabolism or use of fuels (and other chemicals) and then with weekly therapy, maintains the now more normal metabolic process. If patients stop the weekly CAT procedures, their metabolism will revert to the diabetic pattern and their risk of developing diabetic complications increases or reoccurs. The improved quality of life is due to the disappearance of symptoms caused by diabetes, the stabilization, or reversal of the progression of diabetic complications, and improved cellular energy utilization and production.

During the time the patient is in therapy, his/her body undergoes a continual metabolic metamorphosis and the patient’s complex array of medications, including insulin and oral diabetes medications, must be adjusted to take into account the better health of the patient.

The following enzyme pathways are achieved with CAT:
Enzymes induced by achieving an effective high insulin to glucagon ratio: Glucokinase; 6-phosphofructo 1-kinase; 6-phosphofructo 2-kinase; Citrate cleavage enzyme; Acetyl-coa carboxylase; Hmg-coa reductase; Pyruvate kinase.

Enzymes repressed by a highly effective insulin to glucagon ratio: Glucose 6-phosphatase; Fructose 1, 6-biaphosphatase; Phosphoenolpyruvate carboxykinase.

Enzymes activated by a highly effective insulin:glucagon ratio: 6- phosphofructo 2-kinase; Pyruvate kinase (l-isoenzyme); Pyruvate dehydrogenase complex; Acetyl - coa carboxylase; Glycerol phosphate; acyltransferase; Hmg - coa reductase.

Enzymes inactivated by a highly effective insulin: glucagon ratio: Glycogen phosphorylase; Fructose 2, 6 biphosphatase.

These enzymes are largely deficient in both Type 1 and Type 2 diabetic people, their proper action and inactions are what’s missing for proper resting metabolism, and they are restored by CAT.